TL 925
Alternative Names: TL-925Latest Information Update: 23 Jul 2024
At a glance
- Originator Telios Pharmaceuticals
- Class Antiallergics; Eye disorder therapies
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic conjunctivitis; Dry eyes
Most Recent Events
- 21 May 2024 Telios Pharma completes a phase IIb trial in Allergic conjunctivitis in USA (Ophthalmic) (NCT06293820)
- 31 Mar 2024 Telios Pharma initiates a Phase-IIb clinical trials in Allergic conjunctivitis in USA (Ophthalmic) (NCT06293820)
- 11 Mar 2024 Telios Pharma plans a phase IIb trial for Allergic conjunctivitis in USA (Ophthalmic), in March 2024 (NCT06293820)